International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

Review on Recent Advancements in The Treatment of Irritable Bowel Syndrome (IBS)

Prathmesh Sudhir Gogate[1], Prof. Shailesh. G. Jawarkar[2], Dr. N. N. Bobade[3]

ABSTRACT:
Irritable Bowel Syndrome (IBS) is a prevalent and chronic gastrointestinal disorder that affects millions worldwide, characterized by a complex interplay of symptoms, including abdominal pain, bloating, diarrhea, and constipation. Despite its widespread impact, the precise etiology of IBS remains elusive, with genetic, environmental, and psychosocial factors contributing to its pathogenesis. Historically, IBS management has centered on symptom alleviation, often through a combination of dietary interventions, pharmacotherapy, and psychological support. Recent advances in the field, however, have brought about a transformative shift in the approach to IBS care, offering innovative strategies and treatments aimed at addressing the multifaceted nature of the condition.

These emerging paradigms encompass personalized medicine, microbiota-based therapies, and an expanding array of pharmacological treatments that target various aspects of IBS pathophysiology, such as altered gut motility and visceral hypersensitivity. Additionally, the integration of telemedicine and digital health platforms has improved patient access to care and facilitated ongoing symptom management. Notably, Tenapanor (IBSRELA®), the first NHE3 inhibitor approved for treating IBS-C, presents a promising therapeutic option. Ongoing research efforts focus on unraveling the intricate mechanisms underlying IBS, exploring the potential of microbiome-based interventions, and tailoring treatments to individual patients' needs, with the aim of ultimately enhancing the quality of life for those afflicted by this challenging gastrointestinal condition.

KEYWORD: Irritable Bowel Syndrome (IBS) Overview, Abdominal pain, constipation, Diarrhea, IBS Subtype, IBS Management, medication and treatment, IBS future advancement in treatment.

INTRODUCTION:

IBS stands for Irritable Bowel Syndrome. It's a common gastrointestinal disorder that affects the large intestine and can cause symptoms like abdominal pain, bloating, diarrhoea, and constipation. IBS is a chronic condition and its exact cause is not fully understood, but it's believed to involve a combination of factors, including genetics, diet, and stress. It's important for individuals with IBS to work with healthcare professionals to manage their symptoms and develop a personalized treatment plan. Millions of individuals worldwide suffer from Irritable Bowel Syndrome (IBS), a chronic functional gastrointestinal illness. Traditionally, symptom management has been the main emphasis of IBS treatment.



Pharmacotherapy For Abdominal Pain

Pharmacotherapy for abdominal pain in Irritable Bowel Syndrome (IBS) typically focuses on alleviating the pain and discomfort associated with the condition. Some medications that may be used to manage abdominal pain in IBS include:

Antispasmodic drugs like hyoscyamine (Levsin) or dicyclomine (Bentyl) can help reduce intestinal muscle spasms, which can contribute to abdominal pain. Pain Modulators is medications like tricyclic antidepressants (TCAs) or certain selective serotonin reuptake inhibitors (SSRIs) may be prescribed in low doses to help modulate pain perception in the gut.

Peppermint oil capsules, such as enteric-coated peppermint oil, have been shown to provide relief from abdominal pain in some individuals with IBS due to its smooth muscle relaxing properties. Soluble fibre supplements like psyllium (Metamucil) or methylcellulose (Citrucel) may help regulate bowel movements and reduce abdominal discomfort in some cases.

Some probiotics containing specific strains of beneficial bacteria may alleviate IBS symptoms, including abdominal pain, by promoting a healthier gut microbiome. Low-Dose Tricyclic Antidepressants (TCAs) in addition to pain modulation, low doses of TCAs like amitriptyline or nortriptyline may also help with abdominal pain by affecting gut motility.

In some cases, healthcare providers may prescribe medications like lubiprostone (Amitiza) or linaclotide (Linzess), which are specifically approved for the treatment of IBS with constipation (IBS-C) and may help relieve abdominal pain.

Pathogenesis Of Irritable Bowel Syndrome

The exact pathogenesis of Irritable Bowel Syndrome (IBS) is not fully understood, but it is believed to be a complex interplay of several factors, including:

1. Gut Motility: Abnormalities in the movement of the digestive tract, such as hypersensitivity to gut contractions or altered transit times, can contribute to IBS symptoms.
2. Visceral Hypersensitivity: Some individuals with IBS may have increased sensitivity to pain or discomfort in the gut, leading to heightened perception of symptoms.
3. Gut-Brain Axis: The communication between the gut and the brain is thought to play a significant role. Stress, anxiety, and psychological factors can influence gut function and exacerbate IBS symptoms.

4. Microbiome Dysbiosis: Imbalances in the gut microbiota (dysbiosis) have been associated with IBS. Changes in the composition and diversity of gut bacteria may contribute to symptom development.
5. Immune Activation: Some studies suggest that immune system activation in the gut may contribute to IBS symptoms in some individuals.
6. Genetic Factors: There is evidence that genetics may play a role in predisposing some people to IBS, although specific genes have not been definitively identified.
7. Dietary Triggers: Certain foods or food intolerances, such as lactose or gluten intolerance, can trigger IBS symptoms in susceptible individuals.
8. Infections: Gastrointestinal infections can sometimes lead to post-infectious IBS (PI-IBS), where symptoms persist after the infection has cleared.

Management Strategies Conclusion:

Irritable Bowel Syndrome is a common gastrointestinal disorder with a multifactorial etiology, complex clinical presentation, and significant impact on patients' lives. While its exact cause remains elusive, advancements in research and a multidisciplinary approach to management have improved our understanding and treatment options. Future research will likely continue to shed light on the underlying mechanisms of IBS and offer more effective therapies, ultimately improving the quality of life for those affected by this condition**.** lifestyle changes, pharmacotherapy, and psychological interventions. Dietary interventions may include the low FODMAP diet, which restricts certain fermentable carbohydrates, and fibre supplementation. Medications such as antispasmodics, laxatives, and antidepressants may be prescribed based on the predominant symptoms.

Pharmacotherapy for diarrhoea	
Peripheral opiod agonist	Loperamide, Diphenoxylate and difenoxin
Bile acid sequestrant	Cholestyramine Colesevelam Colestipol
5- HT3 receptor antagonist	Ramosetron Ondansetron Alosetron
Mixed opioid agonist	Eluxadoline
Antibiotics	Rifaximin
Pharmacotherapy for constipation	
Soluble Fiber	Psyllium
Laxative	Lactulose, magnesium citrate & polyethlene glycol
Gaunylate cyclase -C agonist	Linaclotide
Type 2 chloride channel activator	Lubiprostone

Pharmacotherapy for abdominal pain	
Antispasmodics	Dicyclomine Mebeverine Otilonium Peppermide oil
Peripheral opioid agonists	Trimebutine
Tricyclic antidepressant	Desipramine Amitriptyline
Selective serotonin reuptake inhibitor	Paroxetine Sertraline

Dietary Interventions

Advancements in dietary management include the refinement of the low FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) diet and its integration into clinical practice. Moreover, emerging evidence suggests that modifying dietary fiber intake and introducing prebiotics may benefit IBS patients.

Personalized Medicine

Advancements in personalized medicine are revolutionizing IBS treatment. Biomarkers, genetic profiling, and microbiome analysis enable tailored therapeutic approaches, ensuring more effective outcomes for individual patients.

Pharmacological Treatments:

New pharmaceuticals are under investigation for IBS treatment. Serotonin receptor modulators, selective 5-HT3 antagonists, and non-absorbable antibiotics are among the drug classes showing promise in clinical trials. These medications target various aspects of IBS pathophysiology, such as altered motility and visceral hypersensitivity.

Psychological and Mind-Body Therapies

Psychological therapies, including cognitive-behavioural therapy (CBT) and gut-directed hypnotherapy, continue to be essential in IBS management. Recent studies emphasize their effectiveness in addressing the gut-brain axis dysfunction that plays a pivotal role in IBS.

Telemedicine and Digital Health

The rise of telemedicine and digital health platforms has improved access to IBS care, enabling remote monitoring, symptom tracking, and virtual consultations. These tools enhance patient engagement and support ongoing symptom management.

Tenapanor OR IBSRELA®

The first and only NHE3 inhibitor to receive FDA approval for treating adult IBS-C is IBSRELA® (tenapanor). As evidenced by the Phase 3 clinical studies, IBSRELA, a first-in-class NHE3 inhibitor, offers a novel mechanism of action and remarkable efficacy results to address the various abdominal symptoms and constipation that are often experienced by patients with IBS-C. inhibitor of sodium/hydrogen exchanger 3 (NHE3) with a localized effect. decreases the amount of salt absorbed from the colon and small intestine, which causes the intestinal lumen to secrete more water, the intestinal transit time to speed up, and the consistency of the stool to become softer. Additionally demonstrated in animal models to lessen intestinal permeability and visceral hypersensitivity, which in turn reduces stomach discomfort.

Future Directions

Ongoing research aims to unravel the complex pathophysiology of IBS and develop more targeted treatments. Advancements in gut microbiome research and the potential role of the microbiota in IBS pathogenesis hold promise for future therapeutic interventions. Additionally, personalized medicine approaches may help tailor treatments to individual patients' needs.

Microbiota-Based Therapies

One of the most exciting developments in IBS treatment is the emergence of microbiota-based therapies. Faecal microbiota transplantation (FMT) and microbiome-targeted interventions show promise in restoring gut microbial balance and alleviating IBS symptoms. Research is ongoing to identify specific microbial signatures associated with IBS subtypes for personalized treatment approaches.



Subtype	Treatment
IBS-C (Constipation-Predominant)	• Dietary modification: High diet, increased water intake. • Medication: laxatives, stool softeners (under medical guidance). • Lifestyle changes: regular exercise, establish a bathroom routine.
IBS-M (Mixed Bowel Habits)	• Dietary Modifications: balance diet considering both constipation and diarrhoea triggers. • Medications: Tailored based on predominate symptoms. -stress management: essential due to stress-triggered symptoms.
IBS-D (Diarrhoea predominant)	• Dietary Modification: low-FODMAP diet, avoidance of trigger food. • Medication: antispasmodics, ant-diarrheal drug. • Stress management: mindfulness, medication. • Probiotics: Consult a healthcare provider for recommendations.

Class	Agent in class	Dosage form	MOD	Indication	AEs	Place in therapy
Serotonin (5-HT4) Receptor Agonist	Tegaserod	Oral tablet	A partial neuronal agonist of the 5-HT4 receptor that reduces visceral sensation while stimulating intestinal secretion and the peristaltic reflex.	When there is no other therapeutic option, women (less than 55 years old) who have IBS-C or CIC should have emergency treatment.	Back pain, nausea, headache, migraine, dizziness, diarrhoea, and flatulence	Was taken off the market because of the possible danger of cardiovascular problems; it is now only accessible for emergency therapy with FDA approval.
Sodium/Hydrogen Exchanger 3 Inhibitor (NHE3)	Tenapanor	Oral tablet	Inhibitor of sodium/hydrogen exchanger 3 (NHE3) with a localized effect. decreases the amount of salt absorbed from the colon and small intestine, which causes the intestinal lumen to secrete more water, the intestinal transit time to speed up, and the consistency of the stool to become softer. Additionally demonstrated in animal models to lessen intestinal permeability	Management of adult IBS-C.	Gas, diarrhoea, and distension of the abdomen	Used to treat refractory IBS-C in both men and women.

			and visceral hypersensitivity, which in turn reduces stomach discomfort.			
Chloride Channel Activators	Lubiprostone	Oral tablet	Bicyclic fatty acid stimulates intestinal fluid secretion and motility by acting locally as a chloride channel (CIC-2) activator at the apical section of the gut.	Treatment for adult female patients with opioid-induced constipation associated with persistent non-cancer pain and chronic idiopathic constipation (CIC).	Diarrhoea, nausea, and headaches	Used to treat women with refractory IBS-C.
Guanylate cyclase-C (GCC) agonist	Plecanatide	Oral tablet	GCC agonist that affects the intestinal epithelium's luminal surface. GI transit time reduces and intestinal fluid increases. Viscosity-related pain may also be lessened by increased extracellular cGMP through a decrease in pain-sensing neuron activity.	Therapy for adults with CIC and IBS-C.	Diarrhoea	Used to treat refractory IBS-C in both men and women.
	Linaclotide	Oral tablet			Flatulence, diarrhoea, and abdominal pain	

Table listing the available treatments for IBS-C along with their indications, mechanisms of action, and side effects

CONCLUSION:

Irritable Bowel Syndrome is a common gastrointestinal disorder with a multifactorial etiology, complex clinical presentation, and significant impact on patients' lives. While its exact cause remains elusive, advancements in research and a multidisciplinary approach to management have improved our understanding and treatment options. Future research will likely continue to shed light on the underlying mechanisms of IBS and offer more effective therapies, ultimately improving the quality of life for those affected by this condition.

REFERENCE:

1. Chapman RW, Stanghellini V, Geraint M, Halphen M. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol. 2013; 108: 1508-1515.
2. Tack J, Camilleri M, Chang L, et al. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012; 35: 745-767.
3. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008; 358: 2344-2354.
4. Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostonein patients with constipation-associatedirritable bowel syndrome –results of two randomized, placebo-controlledstudies. Aliment Pharmacol Ther. 2009; 29: 329-341.
5. Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012; 107: 1702-1712.
6. Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012; 107: 1714-1724.
7. Nelson AD, Black CJ, Houghton LA, et al. Systematic review and network meta-analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome. Aliment Pharmacol Ther. 2021; 54: 98-108.
8. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015; 313: 949-958.
9. Martinez-Vazquez MA, Vazquez-Elizondo G, Gonzalez-Gonzalez JA, et al.Effect of antispasmodic agents, alone or in combination, in the treatment of irritable bowel syndrome: systematic review and meta-analysis. Rev Gastroenterol Mex. 2012; 77: 82-90.
10. Delvaux M, Wingate D. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. J Int Med Res. 1997; 25: 225-246.
11. Gorard DA, Libby GW, Farthing MJ. Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome. Dig Dis Sci. 1995; 40: 86-95.
12. Salari P, Abdollahi M. Systematic review of modulators of benzodiazepine receptors in irritable bowel syndrome: is there hope? World J Gastroenterol. 2011; 17: 4251-4257.
13. Leventer SM, Raudibaugh K, Frissora CL, et al. Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Aliment Pharmacol Ther. 2008; 27: 197-206.

14. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorder. *Gastroenterology*. 2006;130(5):1480–1491. [PubMed] [Google Scholar]
15. Doshi JA, Cai Q, Buono JL, et al. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population. *J Manag Care Spec Pharm*. 2014;20(4):382–390. [PMC free article] [PubMed] [Google Scholar]
16. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. *JAMA*. 2015;313(9):949–958. [PubMed] [Google Scholar]
17. Viberzi [package insert]. Parsipanny, NJ: Actavis Pharma, Inc. 2015 [Google Scholar]
18. Xifaxan [package insert]. Bridgewater, NJ: Salix Pharmaceuticals. 2015 [Google Scholar]
19. Amitiza [package insert]. Bethesda, MD: Sucampo Pharma Americas, LLC. 2013 [Google Scholar]
20. Linzess [package insert]. Cincinnati, OH; Forest Pharmaceuticals, Inc. 2015 [Google Scholar]
21. IBS in America Survey Summary Findings: December 2015. The American Gastroenterological Association. [Accessed July 25,
22. 2016]. http://ibsinamerica.gastro.org/files/IBS_in_America_Survey_Report_2015-12-16.pdf
23. Trinkley KE, Sill BE, Porter K, Nahata MC. Prescribing patterns for outpatient treatment of constipation, irritable bowel syndrome-related constipation, and opioid-induced constipation: a retrospective cross-sectional study. *J Manag Care Spec Pharm*. 2015;21(11):1077–1087. [PMC free article] [PubMed] [Google Scholar]
24. Hayes PA, Fraher MH, Quigley EMM. Irritable bowel syndrome: the role of food in pathogenesis and management. *Gastroenterol Hepatol (N Y)*. 2014;10(3):164–174. [PMC free article] [PubMed] [Google Scholar]